The World Health Organization (WHO) estimates that around 100,800 solid organ transplants are performed worldwide each year, including 69,400 kidney transplants, 20,200 liver transplants, 5,400 heart transplants, 3,400 lung transplants, and 2,400 pancreas transplants. The photopheresis products market is expected to grow at a compound annual growth rate of 6% for the forecast period. The market for photopheresis products is projected to expand as the incidence of autoimmune disorders and the number of organ transplants rise. Photopheresis is a medical treatment that separates white blood cells using a device. Before the patient receives the blood, such white cells are subjected to an 8-methoxy psoralen therapy, followed by UVA irradiation. These white cells are the root cause of sickness. The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.

According to scientists at the National Institute of Environmental Health Sciences (NIEHS), autoimmune diseases appear to be on the rise in the United States. Furthermore, during the forecast period, factors such as developing healthcare infrastructure, technological advancements, and a growing old-age population will propel the market for photopheresis products even further. The ongoing growth of partnerships between significant players in the field of photopheresis will tend to improve understanding of the influence of photopheresis on immunological modulations under a variety of intensive and critical settings, which will benefit the growth of photopheresis products. However, on other hand, due to the high cost of ECP therapy, the global market for photopheresis products may experience a slowdown.ECP therapy costs roughly US$8000 per treatment in the United States, and each individual must take the treatment every two weeks for one year to complete the treatment.

Browse full report at https://www.acutemarketreports.com/report/photopheresis-market

Based on regional segmentation, the photopheresis products market is segmented into North America, Latin America, Europe, Asia Pacific, the Middle East and Africa, and the rest of the globe. The global photopheresis products market was dominated by North America. This region's growth can be attributed to favorable government legislation for diseases such as Cytotoxic T-cell lymphoma (CTL), graft-versus-host disease (GVHD), and lung transplants, all of which are treated with extracorporeal photopheresis (ECP) therapy. Autoimmunity is one of the top ten leading causes of death in female children and women of all ages up to 64, according to the American Autoimmune Related Diseases Association (AARDA). Furthermore, the availability of blood processing centers and modern apheresis are two of the most important factors maintaining the region's dominance. The Asia Pacific and Europe regions are expected to grow at a significant rate during the forecast period.

Fresenius Kabi AG, Haemonetics Corporation, Macopharma, Mallinckrodt Pharmaceuticals, Terumo Corporation, Med Tech Solutions GmbH, and PIT Medical Systems are the major player in the photopheresis products market. Players have employed a range of marketing techniques to stay competitive in the worldwide photopheresis products market, including new product launches, growth, joint ventures, and acquisitions.

Key Market Movements

• The rising incidence of autoimmune diseases is the key factor driving the market.
• High-cost of ECP therapy is a major concern.
• ECP therapy costs roughly US$8000 per treatment in the United States, and each individual must take the treatment every two weeks for one year to complete the treatment.
• The closed systems segment retains a dominant share due to rising autoimmune illnesses.
• North America is the leading market, however, Asia Pacific and Europe are growing significantly.
• The key players include Fresenius Kabi AG, Haemonetics Corporation, Macopharma, Mallinckrodt Pharmaceuticals, Terumo Corporation, Med Tech Solutions GmbH, and PIT Medical Systems.
• The key strategy of these companies includes research and development, mergers, acquisition, and product launches.

The Photopheresis Products Market Segmentation

*Detailed segments are available on the report page